SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 9.99% Stake in SAB Biotherapeutics

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have reported a 9.99% beneficial ownership stake in SAB Biotherapeutics, Inc., holding 1,024,335 shares of common stock.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G, disclosing their beneficial ownership in SAB Biotherapeutics, Inc.
• The Reporting Persons collectively beneficially own 1,024,335 shares of Common Stock, representing 9.99% of the class.
• This ownership includes shares underlying warrants to purchase Series A-3 Preferred Stock, which are convertible into Common Stock.
• The conversion of Series A-3 Preferred Stock is subject to a limitation, preventing the Reporting Persons from beneficially owning more than 9.99% of the outstanding shares after conversion.
• The percentage of class is calculated based on 9,229,274 shares outstanding as of November 1, 2024, as reported in the Company's Quarterly Report on Form 10-Q filed on November 6, 2024, plus the 1,024,335 shares held by the Reporting Persons.
• RTW Investments, LP, a Delaware limited partnership, acts as an investment adviser to certain funds (the "RTW Funds").
• Roderick Wong, M.D. is the Managing Partner and Chief Investment Officer of RTW Investments.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• RTW Master Fund Ltd. and RTW Innovation Master Fund Ltd., both RTW Funds, each have the right to receive or direct dividends or proceeds from the sale of more than 5% of the Shares.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant beneficial ownership stake by an institutional investor. While not directly indicative of operational performance, a substantial investment by a specialized fund like RTW Investments can be viewed as a neutral to slightly positive signal of confidence in the company's value or potential.

Positives

• The disclosure of a significant beneficial ownership stake by an institutional investor like RTW Investments can signal confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business, indicating a passive investment rather than an activist intent to influence control.

Future Outlook

The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Roderick Wong, M.D. on behalf of RTW Investments, LP and himself)

Industry Context

This filing is a standard regulatory disclosure of a significant ownership stake by an institutional investment firm in a publicly traded company. It reflects an investment decision by RTW Investments, a firm specializing in life sciences, which aligns with the typical investment patterns within the biotechnology or pharmaceutical sector where such firms often take positions in promising companies.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially share price.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the investment is passive.

Key Dates

Keywords

SAB Biotherapeutics, RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Investment Adviser, Institutional Investor